Dry eye

Patient with dry eye disease using eye drops

Stem cell dry eye therapy could offer rapid and total relief

3 November 2022

The US Food and Drug Administration (FDA) has approved the Phase III clinical trial design for BRIM Biotechnology’s lead candidate for dry eye disease (DED), BRM421. BRIM will submit the Phase III study protocol to the FDA later this year.  BRM421 is a novel, first-in-class regenerative peptide therapy which, if successful, could offer patients full […]